trial

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

NCTId NCT06482554
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 80 (estimated)
Sponsored by Louisiana State University Health Sciences Center Shreveport
Primary completion 2026-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
80 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2024-06
Primary completion
2026-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Lumateperone (Caplyta)Risperidone

Sponsors

Louisiana State University Health Sciences Center ShreveportLead Sponsor

Investigators

1
Shawn McNeil, MDPrincipal Investigator

Sites

1 total
Shreveport, United States

Linked catalysts

1
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. — primary completion2026-12

Facts & assertions

4 sourced
Enrollment
80
Phase
PHASE3
Primary Completion Date
2026-12
Status
RECRUITING
relationships
The graph out of here
drug
Lumateperone (Caplyta)
drug
Risperidone
drug
lead_sponsor
Louisiana State University Health Sciences Center Shreveport
company
indication
Schizophrenia; Psychosis
indication
Psychotic Disorders
indication
Lethargy
indication
investigator
Shawn McNeil, MD
person